comparemela.com

Latest Breaking News On - Michael castagna - Page 10 : comparemela.com

MannKind (MNKD) Granted Parent for New Clofazimine Formulation

MannKind (MNKD) Granted Parent for New Clofazimine Formulation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMichael castagnaTrademark officeMannkind corporationMannkind corporation nasdaqUnited states patentChief executive officer

Danbury s MannKind Corp receives patent for NTM lung disease treatment

Danbury-headquartered MannKind Corp. announced the U.S. Patent and Trademark Office issued a new patent (No. 11,793,808) covering the company’s clofazimine inhalation suspension (MNKD-101), which is under development for the potential treatment of nontuberculous mycobacterial (NTM) lung disease.

Michael castagnaTrademark officeMannkind corpDanbury headquartered mannkind

MannKind Corporation (NASDAQ:MNKD) is a favorite amongst institutional investors who own 53%

Key Insights Given the large stake in the stock by institutions, MannKind's stock price might be vulnerable to their.

Michael castagnaBlackrock incVanguard group incGlobal advisors incMannkind corporationStreet global advisorsVanguard groupInstitutional investorsNdividual investors

MannKind (NASDAQ:MNKD) Coverage Initiated by Analysts at Wedbush

Wedbush initiated coverage on shares of MannKind (NASDAQ:MNKD – Free Report) in a research report released on Monday morning, MarketBeat reports. The firm issued an outperform rating on the biopharmaceutical company’s stock. Wedbush also issued estimates for MannKind’s Q3 2023 earnings at ($0.02) EPS, Q4 2023 earnings at ($0.03) EPS, FY2023 earnings at ($0.10) EPS, […]

United statesDavid thomsonMichael castagnaInternational assets investment managementTopco ltdMannkind corporationFirst horizon advisors incCetera advisorsCantor fitzgeraldMannkind company profileFree reportModerate buyGet free reportAssets investment managementHorizon advisorsKind corporation

Insider Selling: MannKind Co (NASDAQ:MNKD) CEO Sells 10,000 Shares of Stock

MannKind Co. (NASDAQ:MNKD – Get Free Report) CEO Michael Castagna sold 10,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $4.61, for a total transaction of $46,100.00. Following the sale, the chief executive officer now directly owns 2,436,039 shares of the […]

United statesMichael castagnaAmerican international group incMannkind company profileProshare advisorsMannkind corporationCantor fitzgeraldAmeritas investment partners incMannkind coGet free reportInvestment partnersShare advisorsWisconsin investment boardAmerican international groupInternational groupKind corporation

vimarsana © 2020. All Rights Reserved.